MicroRNA Let-7a-1: A Potential Drug Target and Biomarker (G406881)

Target Name: MIRLET7A1

NCBI ID: G406881

MIRLET7A1

MicroRNA Let-7a-1: A Potential Drug Target and Biomarker

MicroRNA let-7a-1 (miRNA let-7a-1) is a non-coding RNA molecule that plays a critical role in various biological processes in the cell. It is a key regulator of cell proliferation and has been implicated in a wide range of cellular processes, including cell adhesion, migration, and apoptosis. In this article, we will discuss the research on miRNA let-7a-1 as a drug target and its potential as a biomarker for various diseases.

The let-7a-1 microRNA is a member of the miRNA family, which is a subset of non-coding RNAs that are involved in post-transcriptional gene regulation. miRNAs are small, non-coding RNAs that are derived from mRNAs by a process called translation initiation. They are involved in the regulation of gene expression and have been implicated in various cellular processes, including cell growth, differentiation, and apoptosis.

One of the unique features of let-7a-1 is its expression pattern. Let-7a-1 is predominantly expressed in the brain, and its levels are highly variable across different brain regions. It is also expressed in other tissues and organs, including liver, pancreas, and heart. The expression pattern of let-7a-1 is highly consistent with its function, as it is involved in the regulation of brain development and function.

let-7a-1 has been shown to play a critical role in the regulation of cell proliferation and cell cycle progression. It has been shown to inhibit the G1 checkpoint, which is a critical checkpoint that ensures that cells only enter the S phase of the cell cycle when they are ready to synthesize new DNA. The inhibition of the G1 checkpoint by let-7a-1 has been shown to lead to increased cell proliferation and the formation of cancerous tumors.

let-7a-1 has also been shown to play a critical role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. Let-7a-1 has been shown to regulate the formation of tight junctions, which are a type of adhesion protein that helps to maintain the integrity of tissues and organs.

let-7a-1 has also been shown to play a critical role in the regulation of cell apoptosis. Apoptosis is the process by which cells die, and it is a natural and necessary part of cell life cycle. Let-7a-1 has been shown to regulate the programmed cell death, which is the process by which cells are instructed to die at the end of their lives.

In addition to its role in cell proliferation and apoptosis, let-7a-1 has also been shown to play a critical role in the regulation of inflammation. It has been shown to regulate the production of pro-inflammatory cytokines, which are important drivers of inflammation.

let-7a-1 has also been shown to play a critical role in the regulation of gene expression. It has been shown to interact with several important transcription factors, including NF-kappa-B, AP-1, and STAT3. These transcription factors are responsible for regulating the expression of many important genes that are involved in various cellular processes.

In conclusion, let-7a-1 is a microRNA that plays a critical role in various cellular processes. Its expression pattern is highly variable and its functions are highly diverse. Its potential as a drug target or biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of let-7a-1 in various cellular processes and to determine its potential as a drug or biomarker.

Protein Name: MicroRNA Let-7a-1

The "MIRLET7A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIRLET7A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets